Bringing innovative ADC and SMDC medicines to cancer patients around the world
Founded in 2018, CanWell Pharma is led by several highly accomplished veterans who have an average of 25 years of experience in drug discovery and development in both U.S. and China biopharmaceutical industries. CanWell is dedicated to developing its proprietary first-in-class and best-in-class oncology products to address difficult-to-treat advanced cancers. CanWell is developing a rich R&D pipelines under our technology platforms.
Our Mission
Our mission at CanWell is to develop innovative treatments that harness the power of the immune system to fight cancer. We are devoted to leveraging the latest advances to further explore and develop a variety of innovative therapies. With a focus on collaboration, innovation and patient-centered care, we strive to be at the forefront of cancer therapy and bring new hope to patients and their families.
Antibody Drug Conjugate
Small Molecule Drug Conjugate
Latest News
CanWell Pharma Announces Participation in the AACR Annual Meeting 2026.
San Diego, CA – CanWell Pharma is pleased to announce its participation in the AACR Annual Meeting 2026, taking place from April 17–22, 2026, at the San Diego Convention Center. The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health ca…
CANWELL Pharma Received U.S. FDA Orphan Drug Designation for CAN1012 in the Treatment of Soft Tissue Sarcoma
March 3, 2026, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to CAN1012, the company’s proprietary IFNα-biased TLR7 agonist, for the treatment of Soft Tissue Sarcoma (STS). CAN1012 is a novel small-molecule IFNα-biased Toll-like receptor 7 (TLR7) agonist developed…
A novel Dual-payload HER2 Targeted ADC, CAN016 as a Clinical Candidate to Overcome Enhertu Resistance
Resistance to ADC Enhertu (DS-8201) therapy presents a significant clinical challenge for patients with HER2-positive cancers. To address this unmet need, we have developed a novel dual-payload ADC (CAN016), conjugating both MMAE and exatecan to a HER2 antibody, based on our proprietary StarLinkerTM…
CanWell Pharma Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, CA – CanWell Pharma is pleased to announce its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), taking place from January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco. As one of the world’s most prestigious healthcare investment symposium…